Home / Companies / News / Jubilant Life launches generic version of remdesivir for Covid-19 treatment

Jubilant Life launches generic version of remdesivir for Covid-19 treatment

The injectable drug, under the brand name 'JUBI-R', is priced at Rs 4,700 per vial of 100 mg

remdesivir, coronavirus, drugs, covid, pharma

Premium

The drug will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner, the statement said.

Press Trust of India New Delhi

2 min read Last Updated : Aug 03 2020 | 9:40 PM IST

Drug firm Jubilant Life Sciences on Monday said it has launched the generic version of antiviral drug remdesivir in India for the treatment of Covid-19 patients.

The injectable drug, under the brand name 'JUBI-R', is priced at Rs 4,700 per vial of 100 mg.

The company will make the drug available to over 1,000 hospitals providing Covid-19 treatment, Jubilant Life Sciences said in a statement.

In order to increase the accessibility of the drug to patients below the poverty line and to front-line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of the Jubilant Group, is launching programs in India aimed at its

Topics : Coronavirus Jubilant Life Sciences

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in